IMbrave251: Final analysis of atezolizumab (atezo) + lenvatinib (lenva) or sorafenib (sora) vs lenva or sora alone in locally advanced or metastatic hepatocellular carcinoma (LA/mHCC) previously treated with atezo and bevacizumab (bev).
Year: 2026
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: University of Toronto, Toronto General Hospital, Princess Margaret Cancer Centre, Cliniques Universitaires Saint-Luc, Genentech, CHA University Bundang Medical Center, CHA University, Chi Mei Medical Center, Roche (Switzerland), National Cancer Center, University Health Network, Kindai University, University College London, Myongji Hospital, National Cancer Center Hospital, Nanjing General Hospital of Nanjing Military Command, Centre Hospitalier Universitaire de Nantes, Clinica Universidad de Navarra
Language: English
Subfield: Hepatology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funder: F. Hoffmann-La Roche
OpenAlex ID: W7162556983